was generated using SuperScript RNase H reverse transcriptase (Gibco/BRL) and a primer complimentary to a sequence in the 3'-untranslated region of the human GRP78/BiP mRNA transcript (AB10230; 5'-TATTACAGCACTAGCAGATCAGTG-3') (SEQ ID NO:1). For PCR amplification, the forward primer AB10231 (5'-CTTAAGCTT**GCCACC**ATGAAGCTCTCCCTGGTGGCCGCG-3') (SEQ ID NO:2) contained a Kozak consensus sequence (bold) prior to the initiating ATG and a terminal *Hind*III restriction site (underlined). The reverse primer AB10232 (5'-AGGCCTCGAGCTACAACTCATCTTTTTCTGCTGT-3') (SEQ ID NO:3) contained a terminal *Xho*I restriction site (underlined) adjacent to the authentic termination codon of the GRP78/BiP cDNA. PCR reactions took place in a final volume of 50 µl containing 2 µl of the RT reaction, 100 ng of primers, 2.5 U *Taq* polymerase (Perkin-Elmer, Mississauga, ON) in a buffer consisting of 1.5 mM $MgCl_2$, 50 mM KCl, 10 mM Tris-HCl (pH 8.8) and 0.5 mM of each dNTP. All samples were subjected to amplification in a DNA thermal cycler 480 (Perkin-Elmer) with a step programme of 30 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min. The amplified GRP78/BiP cDNA was separated on a 0.8% agarose-TBE gel containing ethidium bromide, purified from the agarose gel using the QIAEX gel extraction kit (Qiagen, Mississauga, ON) and ligated into T-ended pBluescript (KS) (Stratagene, La Jolla, CA). The ligation mixture was then used to transform competent DH5α cells (Gibco/BRL). Plasmid DNA was isolated from transformed cells using the QIAEX miniprep kit (Qiagen), digested with *Hind*III and *Xho*I, and the GRP78/BiP cDNA insert purified from agarose. The GRP78/BiP cDNA insert was ligated into the *Hind*III/*Xho*I site of the mammalian expression vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA) to produce the recombinant plasmid, pcDNA3.1(+)-GRP78/BiP. Authenticity of the GRP78/BiP cDNA sequence was confirmed by fluorescence-based double stranded DNA sequencing (MOBIX).

(NE. Page 46 is missing)

Please replace the paragraph beginning at page 46, line 3, with the following rewritten paragraph:

SEQ ID NO:4

Human GRP78/BiP amino acid sequence

MKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIA
NDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQ
QDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKK

VTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEK
NILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKK
KTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKF
EELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGK
EPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKL
IPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRG
VPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFA
EEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEEKIE
WLESHQDADIEDFKAKKKELE EIVQPIISKLYGSAGPPPTGEEDTAEKDEL

Please replace the paragraph beginning at page 46, line 20, with the following rewritten paragraph:

SEQ ID NO: 5

Human GRP78/BiP mRNA sequence

```
1    ACTGGCTGGC AAGATGAAGC TCTCCCTGGT GGCCGCGATG CTGCTGCTGC TCAGCGCGGC
61   GCGGGCCGAG GAGGAGGACA AGAAGGAGGA CGTGGGCACG GTGGTCGGCA TCGACCTGGG
121  GACCACCTAC TCCTGCGTCG GCGTGTTCAA GAACGGCCGC GTGGAGATCA TCGCCAACGA
181  TCAGGGCAAC CGCATCACGC CGTCCTATGT CGCCTTCACT CCTGAAGGGG AACGTCTGAT
241  TGGCGATGCC GCCAAGAACC AGCTCACCTC CAACCCCGAG AACACGGTCT TTGACGCCAA
301  GCGGCTCATC GGCCGCACGT GGAATGACCC GTCTGTGCAG CAGGACATCA AGTTCTTGCC
361  GTTCAAGGTG GTTGAAAAGA AAACTAAACC ATACATTCAA GTTGATATTG GAGGTGGGCA
421  AACAAAGACA TTTGCTCCTG AAGAAATTTC TGCCATGGTT CTCACTAAAA TGAAAGAAAC
481  CGCTGAGGCT TATTTGGGAA AGAAGGTTAC CCATGCAGTT GTTACTGTAC CAGCCTATTT
541  TAATGATGCC CAACGCCAAG CAACCAAAGA CGCTGGAACT ATTGCTGGCC TAAATGTTAT
601  GAGGATCATC AACGAGCCTA CGGCAGCTGC TATTGCTTAT GGCCTGGATA AGAGGGAGGG
661  GGAGAAGAAC ATCCTGGTGT TTGACCTGGG TGGCGGAACC TTCGATGTGT CTCTTCTCAC
721  CATTGACAAT GGTGTCTTCG AAGTTGTGGC CACTAATGGA GATACTCATC TGGGTGGAGA
781  AGACTTTGAC CAGCGTGTCA TGGAACACTT CATCAAACTG TACAAAAAGA AGACGGGCAA
841  AGATGTCAGG AAAGACAATA GAGCTGTGCA GAAACTCCGG CGCGAGGTAG AAAAGGCCAA
901  ACGGGCCCTG TCTTCTCAGC ATCAAGCAAG AATTGAAATT GAGTCCTTCT ATGAAGGAGA
961  AGACTTTTCT GAGACCCTGA CTCGGGCCAA ATTTGAAGAG CTCAACATGG ATCTGTTCCG
1021 GTCTACTATG AAGCCCGTCC AGAAAGTGTT GGAAGATTCT GATTTGAAGA AGTCTGATAT
1081 TGATGAAATT GTTCTTGTTG GTGGCTCGAC TCGAATTCCA AAGATTCAGC AACTGGTTAA
1141 AGAGTTCTTC AATGGCAAGG AACCATCCCG TGGCATAAAC CCAGATGAAG CTGTAGCGTA
1201 TGGTGCTGCT GTCCAGGCTG GTGTGCTCTC TGGTGATCAA GATACAGGTG ACCTGGTACT
1261 GCTTGATGTA TGTCCCCTTA CACTTGGTAT TGAAACTGTG GGAGGTGTCA TGACCAAACT
```